Scancell
Scancell is a United Kingdom-based biotechnology company running 2 late-stage cancer trials in melanoma, triple-negative breast cancer and renal cell carcinoma.
Overview
Scancell, based in Oxford, the United Kingdom, is a biotechnology company. Scancell is a late-stage clinical company developing active immunotherapies designed to enhance anti-tumour immune responses in cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in melanoma, triple-negative breast cancer, renal cell carcinoma, ovarian cancer and head and neck squamous cell carcinoma. The largest, NCT04079166 (SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)), plans to enrol 173 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyVyriad
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Melanoma and the tag ctgov-sponsor.
- CompanyOncoC4
Shares Renal cell carcinoma, Ovarian cancer, Head and neck squamous cell carcinoma, Melanoma and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag ctgov-sponsor.
- CompanyBioInvent International
Shares Ovarian cancer, Melanoma and the tag ctgov-sponsor.
- CompanyGeorgiamune
Shares Melanoma and the tag ctgov-sponsor.
- CompanyNeonc Technologies
Shares Head and neck squamous cell carcinoma, Melanoma and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Melanoma and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Melanoma and the tag ctgov-sponsor.